ANNEXa-I Deep Dive: Part II

ANNEXa-I Deep Dive Part II Special Guests: Scott Dietrich, PharmD, BCCCP Brian Gilbert, PharmD, MBA, BCCCP, FCCM, FNCS Todd Miano, PharmD, PhD, FCCM   03:13 – Safety/thrombotic findings 21:50 – Questions that remain 26:50 – Practical considerations 41:40 – P&T elevator pitch   Reference List: https://pharmacytodose.com/wp-content/uploads/2024/06/annexai-deep-dive-part-ii-references.pdf   PharmacyToDose.Com @PharmacyToDose [email protected] Learn more about your ad choices. Visit megaphone.fm/adchoices

ANNEXa-I Deep Dive Part I Special Guests: Scott Dietrich, PharmD, BCCCP Brian Gilbert, PharmD, MBA, BCCCP, FCCM, FNCS Todd Miano, PharmD, PhD, FCCM   05:40 – Brief ANNEXa-I study overview 20:40 –Primary composite outcome 26:40 – Anti-FXa levels 30:45 – Statistics/methodology questions   Reference List: https://pharmacytodose.com/wp-content/uploads/2024/06/annexai-deep-dive-part-i-references.pdf   PharmacyToDose.Com @PharmacyToDose [email protected] Learn more about your ad choices. Visit megaphone.fm/adchoices

Literature Review Series January 2024 Special Guests: Haley Torr, PharmD Nick Tran, PharmD   06:55 – Featured Articles 32:55 – PAD-IS articles 37:10 – Cardiology articles 46:00 – Heme articles 51:40 – Potpourri articles 60:05 – Pharmacist-featured articles 67:30 – Sweet Emotion articles   Reference List: https://pharmacytodose.com/wp-content/uploads/2024/06/jan-2024-lrs-references.pdf   PharmacyToDose.Com @PharmacyToDose [email protected] Learn more about your ad choices. Visit megaphone.fm/adchoices

Trial of the Week: PROWESS-SHOCK Special Guest: Paul Szumita, PharmD, FCCM, FASHP, BCCCP, BCPS @paulszumita   03:30 – Background studies/Setting the scene 30:25 – PROWESS-SHOCK discussion/Where are we now   Paul Szumita joins to highlight a June Trial of the Week “Drotrecogin alfa (activated) in adults with septic shock” published in the New England Journal of Medicine in 2012. To fully understand the discussion regarding drotrecogin alfa, Paul and I review the mechanism of action and its proposed action in the treatment of sepsis. Then we review earlier studies and the controversy behind the FDA approval process. Finally, we go into detail on what Clinical Pharmacists were tasked with doing at the time based on treatment protocols or hospital restrictions. Then we dive into the Trial of the Week, discussing the study design and results. What was the mood in ICUs and Pharmacy Departments after this publication? How much did our sepsis care improve from PROWESS to PROWESS-SHOCK? What lessons did we learn with the Xigris FDA approval process? Is there a patient population that could still benefit from drotrecogin alfa treatment? Plus, trial fun facts, issues with calculating APACHE II scores, and so much more. Reference list: https://pharmacytodose.com/wp-content/uploads/2024/06/prowess-shock-trial-of-the-week-references.pdf   PharmacyToDose.Com @PharmacyToDose [email protected] Learn more about your ad choices. Visit megaphone.fm/adchoices

Literature Review Series 2023 Year-In-Review Special Guests: Jacquelyn Crawford, PharmD @jacuronium Kathleen Hartman, PharmD @HartKate8   04:30 – Neurology 11:05 – Cardiology 18:50 – Cardiac Arrest 26:30 – Pulmonary 35:00 – Sepsis 44:05 – Endocrine/Renal 52:30 – Trauma 61:05 – Infectious Diseases   Reference List: https://pharmacytodose.com/wp-content/uploads/2024/06/yir-2023-lrs-references.pdf   PharmacyToDose.Com @PharmacyToDose [email protected] Learn more about your ad choices. Visit megaphone.fm/adchoices

Trial of the Week: Ketamine for EM Agitation Special Guest: Justin Lin, PharmD, BCPS, BCCCP @jjlinpharmd   Justin Lin joins to review the May Trial of the Week “Efficacy of ketamine for initial control of acute agitation in the emergency department: a randomized study” published in the American Journal of Emergency Medicine in 2021. We set the scene by discussing how this research idea started, review the classic agitation presentation at his institution, and highlight evidence comparing pharmacotherapy treatment options prior to this study. Then we dive into the Trial of the Week, discussing the study design and results. What was the biggest pushback from providers or the IRB? Any unique education strategies? Would results stay the same with increased IV push administration? What would the comparator arm be if this study was replicated today? Plus, the most challenging part of this project, Justin’s favorite agent, and so much more.   Reference list: https://pharmacytodose.com/wp-content/uploads/2024/05/ketamine-for-em-agitation-trial-of-the-week-references.pdf   PharmacyToDose.Com @PharmacyToDose [email protected] Learn more about your ad choices. Visit megaphone.fm/adchoices

Sanford Guide Q&A Special Guest: Doug Black, PharmD   04:40 – Doug’s background/Sanford guide introduction 14:20 – Print v. digital guide/included content 34:35 – Tables/tools highlights 41:55 – Doug’s favorites/conclusions   Sanford Guide Website: https://web.sanfordguide.com/   PharmacyToDose.Com @PharmacyToDose [email protected] Learn more about your ad choices. Visit megaphone.fm/adchoices

Code ICH Special Guest: Gabe Fontaine, PharmD, MBA, BCPS, BCCCP, FNCS, FCCM @gabe_fontaine   04:00 – Code ICH and history of ICU bundled care 15:15 – BP control 22:50 – Hemostasis 33:15 – Challenges & future directions   Reference List: https://pharmacytodose.com/wp-content/uploads/2024/05/code-ich-references.pdf   PharmacyToDose.Com @PharmacyToDose [email protected] Learn more about your ad choices. Visit megaphone.fm/adchoices

Trial of the Week: MENDS2 Special Guest: John Devlin, PharmD, BCCCP, MCCM, FCCP @devlinpharmd   03:20 – PADIS background and research introduction 35:25 – MENDS2 discussion   John Devlin joins to review the May Trial of the Week “Dexmedetomidine or Propofol for Sedation in Mechanically Ventilated Adults with Sepsis” the MENDS2 study, published in NEJM in 2021. We set the scene by discussing how John developed an interest with PADIS research, discussing PK/PD sedative properties and considerations, landmark trials prior to MENDS2, and how much background work is required for a large RCT. Then we dive into the MENDS2 trial itself. Any significant findings? Biggest methodologic differences from MENDS2 and previous studies? Most challenging process of blinding? Any potential safety concerns? How to avoid unblinding study patients (and why that’s so important)? Plus, trial fun facts, seeing your name in a NEJM research article, applying MENDS2 findings into daily practice, and so much more.   Reference list: https://pharmacytodose.com/wp-content/uploads/2024/05/mends2-trial-of-the-week-references.pdf   PharmacyToDose.Com @PharmacyToDose [email protected] Learn more about your ad choices. Visit megaphone.fm/adchoices

Rapid Reaction: ANNEXA-I   02:35 – Study design/results 18:30 – Considerations/questions   Reference List: https://pharmacytodose.files.wordpress.com/2024/05/annexa-i-references.pdf   PharmacyToDose.Com @PharmacyToDose [email protected] Learn more about your ad choices. Visit megaphone.fm/adchoices